[Experience in clinical use of primalan (mequitazine) in allergology].
OBJECTIVE
To study efficacy of primalan (mequitasine) in the treatment of allergic rhinoconjunctivitis and chronic recurrent urticaria.


METHODS
The study included 140 patients. Of them, 60 patients had allergic rhinitis, 80 patients had chronic recurrent urticaria. All the patients received primalan (mequitasin) in a dose 10 mg/day (5 mg twice daily or a single dose 10 mg). The disease symptoms and side effects of primalan were assessed for 28 days of the treatment.


RESULTS
Primalan (mequitasin) proved to be highly effective against allergic rhinitis (good and very good response--76%, satisfactory--20%) and chronic recurrent urticaria (the response in 90% patients). Good primalan tolerance was reported. Side effects were moderate and did not require the drug withdrawal (sleepiness in 6.6%, dryness of the mucosa in 5%).


CONCLUSIONS
Primalan (mequitasin) can be recommended for wide application in therapy of allergic rhinitis and chronic recurrent urticaria.
Il'ina
N I
NI
Latysheva
T V
TV
Varfolomeeva
M I
MI
D000293:Adolescent; D000328:Adult; D000368:Aged; D002648:Child; D005260:Female; D006634:Histamine H1 Antagonists / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D006967:Hypersensitivity / Q000145:classification / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D010640:Phenothiazines / Q000009:adverse effects / Q000627:therapeutic use*; D016896:Treatment Outcome
D006634:Histamine H1 Antagonists; D010640:Phenothiazines; C006069:mequitazine